Dement Neurocogn Disord.  2015 Jun;14(2):70-75. 10.12779/dnd.2015.14.2.70.

A Comparison of Apolipoprotein E Polymorphism in Alzheimer's Disease and Subcortical Vascular Dementia in Koreans

• Kim JW
• Kwon OD

• KMID: 2443004
• DOI: http://doi.org/10.12779/dnd.2015.14.2.70

Abstract

BACKGROUND AND PURPOSE
The apolipoprotein E (Apo E) epsilon4 allele is known to be a risk factor for Alzheimer's disease (AD). However, there are debates about the relationship between Apo E epsilon4 frequency and subcortical vascular dementia (SVaD). We compared the frequency of the Apo E epsilon4 allele in AD and SVaD in Koreans.
METHODS
The study was comprised of 400 subjects who visited the Dementia Clinic at Daegu Catholic University from July 2007 to December 2011. Neuropsychological tests, a brain MRI, and blood laboratory tests were performed on all subjects. Two hundred and ninety subjects were AD, 32 subjects were SVaD and 78 subjects were normal. The diagnosis for SVaD was based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and Erkinjuntti criteria, and the diagnosis for AD was based on the DSM-IV and National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's disease and Related Disorders Association criteria. Apo E polymorphism was genotyped in all subjects.
RESULTS
The Apo E epsilon4 allele frequency was 17.4% in AD, 10.9% in SVaD and 8.3% in the normal group (p=0.03). The odds ratio (OR) after age adjustment for AD conferred to the Apo E epsilon4 was 2.04 (p=0.04). But, the OR for SVaD conferred to the Apo E epsilon4 allele was 1.34 (p=0.62), indicating that the Apo E epsilon4 allele does not significantly confer the risk of SVaD.
CONCLUSIONS
Apo E epsilon4 is a reliable predictor of AD but has modest efficacy for predicting SVaD in Koreans.

Keyword

apolipoprotein E; Alzheimer's disease; subcortical vascular dementia

MeSH Terms

Alleles
Alzheimer Disease*
Apolipoproteins E
Apolipoproteins*
Brain
Communication Disorders
Daegu
Dementia
Dementia, Vascular*
Diagnosis
Diagnostic and Statistical Manual of Mental Disorders
Gene Frequency
Magnetic Resonance Imaging
Neuropsychological Tests
Odds Ratio
Risk Factors
Stroke
Apolipoproteins
Apolipoproteins E

Reference

1. Son EJ, Kim JM, Kim YS, Kim BC, Kim MK, Cho KH. Relationships of apolipoprotein E genotypes with vascular risk factors in patients with Alzheimer's disease. J Korean Neurol Assoc. 2003; 21:41–45.

2. Hoshino T, Kamino K, Matsumoto M. Gene dose effect of the APOE-epsilon4 allele on plasma HDL cholesterol level in patients with Alzheimer's disease. Neurobiol Aging. 2002; 23:41–45.

3. Cole GM, Beech W, Frautschy SA, Sigel J, Glasgow C, Ard MD. Lipoprotein effects on Abeta accumulation and degradation by microglia in vitro. J Neurosci Res. 1999; 57:504–520.

4. Elias MF, Beiser A, Wolf PA, Au R, White RF, D'Agostino RB. The preclinical phase of alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000; 57:808–813.

5. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90:8098–8102.

6. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A. 1994; 91:11183–11186.

7. Handelmann GE, Boyles JK, Weisgraber KH, Mahley RW, Pitas RE. Effects of apolipoprotein E, beta-very low density lipoproteins, and cholesterol on the extension of neurites by rabbit dorsal root ganglion neurons in vitro. J Lipid Res. 1992; 33:1677–1688.

8. O'Brien KD, Deeb SS, Ferguson M, McDonald TO, Allen MD, Alpers CE, et al. Apolipoprotein E localization in human coronary atherosclerotic plaques by in situ hybridization and immunohistochemistry and comparison with lipoprotein lipase. Am J Pathol. 1994; 144:538–548.

9. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature. 1996; 380:168–171.

10. Kalaria RN, Cohen DL, Premkumar DR. Apolipoprotein E alleles and brain vascular pathology in Alzheimer's disease. Ann N Y Acad Sci. 1996; 777:266–270.

11. Racchi M, Baetta R, Salvietti N, Ianna P, Franceschini G, Paoletti R, et al. Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content. Biochem J. 1997; 322(Pt 3):893–898.

12. Koudinova NV, Berezov TT, Koudinov AR. Multiple inhibitory effects of Alzheimer's peptide Abeta1-40 on lipid biosynthesis in cultured human HepG2 cells. FEBS Lett. 1996; 395:204–206.

13. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 1994; 17:525–530.

14. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A. 1995; 92:12260–12264.

15. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology. 1995; 45:1092–1096.

16. Kao JT, Tsai KS, Chang CJ, Huang PC. The effects of apolipoprotein E polymorphism on the distribution of lipids and lipoproteins in the Chinese population. Atherosclerosis. 1995; 114:55–59.

17. Siest G, Pillot T, Rgis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM, et al. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem. 1995; 41(8 Pt 1):1068–1086.

18. Kawamata J, Tanaka S, Shimohama S, Ueda K, Kimura J. Apolipoprotein E polymorphism in Japanese patients with Alzheimer's disease or vascular dementia. J Neurol Neurosurg Psychiatry. 1994; 57:1414–1416.

19. Stengrd JH, Pekkanen J, Sulkava R, Ehnholm C, Erkinjuntti T, Nissinen A. Apolipoprotein E polymorphism, Alzheimer's disease and vascular dementia among elderly Finnish men. Acta Neurol Scand. 1995; 92:297–298.

20. Klmn J, Juhsz A, Csszr A, Kanka A, Rimanczy A, Janka Z, et al. Increased apolipoprotein E4 allele frequency is associated with vascular dementia in the Hungarian population. Acta Neurol Scand. 1998; 98:166–168.

21. Molero AE, Pino-Ramrez G, Maestre GE. Modulation by age and gender of risk for Alzheimer's disease and vascular dementia associated with the apolipoprotein E-epsilon4 allele in Latin Americans: findings from the Maracaibo Aging Study. Neurosci Lett. 2001; 307:5–8.

22. Kim KW, Youn JC, Han MK, Paik NJ, Lee TJ, Park JH, et al. Lack of association between apolipoprotein E polymorphism and vascular dementia in Koreans. J Geriatr Psychiatry Neurol. 2008; 21:12–17.

23. Kang HU, Park MY. Apolipoprotein E ɛ4 allele frequency in Korean patients with vascular dementia. J Korean Dement Assoc. 2002; 1:34–38.

24. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994; 7:180–184.

25. Royston MC, Mann D, Pickering-Brown S, Owen F, Perry R, Raghavan R, et al. Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down's syndrome from dementia. Neuroreport. 1994; 5:2583–2585.

26. Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD, et al. Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet. 1996; 58:803–811.